Company: INMB
Filing Date: 2025-12-05
Form Type: 8-K
Source: 0001213900-25-118699
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-12-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On December 1, 2025,
INmune Bio Inc. (the “ Company”) issued a press release announcing new neuroimaging data from its Phase 2 MINDFuL trial of
XPro1595 in patients with early Alzheimer’s disease and elevated neuroinflammation. A copy of the press release is attached herewith
as Exhibit 99.1 and is incorporated herein by reference.

On December 5, 2025,
the Company issued a press release announcing a recently published overview of future applications and research areas for mesenchymal
stromal cell therapies, such as the Company’s CORDStrom™ platform. A copy of the press release is attached as Exhibit
99.2 and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits